|
KMID : 0882419930440020221
|
|
Korean Journal of Medicine
1993 Volume.44 No. 2 p.221 ~ p.227
|
|
|
Mitomycin C, Vinblastine, and Cisplatin(MVP) Combination Chemotherapy for Advanced Non-Small Cell Lung Cancer
|
|
김상위
안명주/서철원/이규형/이정신/고윤석/김우성/김원동/김상희
|
|
|
Abstract
|
|
|
ackground : Advanced non-small cell lung cancer (NSCLC) is still a lethal disease and
one of the most important causes of cancer-related death. Role of systemic chemotherapy
seems to be palliative and showed objective response of 30-40%. We treated 33 patients
with advanced NSCLC with combination therapy of mitomycin C, vinblastine, and cisplatin
(MVP) to evaluate the clinical activity and side effect of this combination.
Methods : Cisplatin was infused intravenously on day 1 at the dose of 60 mg/m^2 with
pre- and post-hydration and mitomycin C 6 mg/m^2 (maximum 10 mg) and vinblastine 6
mg/m^2 (maximum 8 mg) were given intravenously on day 2. The treatment was repeated
every 3-4 weeks, and at least 2 cycles of chemotherapy were administered.
Results : Nine patients (27%) had partial responses and no one had complete response.
Median response duration was 16 weeks, range (4+to 28 weeks), The toxicity included mild
and transient nausea/vomiting, mild to moderate leukopenia, and mild peripheral neuropathy.
All of them were well tolerated and recovered fully before the next cycle of chemotherapy.
Conclustion : MVP combination chemotherapy is moderately active against advanced
NSCLC and relatively well tolerated.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|